Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 2
2006 1
2007 2
2008 2
2009 2
2010 3
2011 1
2012 5
2013 3
2014 2
2015 2
2016 5
2017 3
2019 1
2020 4
2021 1
2022 1
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF, Bruni S, Mauro FL, Schillaci R. Mercogliano MF, et al. Among authors: schillaci r. Cancers (Basel). 2023 Mar 26;15(7):1987. doi: 10.3390/cancers15071987. Cancers (Basel). 2023. PMID: 37046648 Free PMC article. Review.
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, Dupont A, Rocha D, Fernández EA, Deza EG, Lopez Della Vecchia D, Barchuk S, Figurelli S, Lasso D, Friedrich AD, Santilli MC, Regge MV, Lebersztein G, Levit C, Anfuso F, Castiglione T, Elizalde PV, Mercogliano MF, Schillaci R. Bruni S, et al. Among authors: schillaci r. J Immunother Cancer. 2023 Mar;11(3):e005325. doi: 10.1136/jitc-2022-005325. J Immunother Cancer. 2023. PMID: 36889811 Free PMC article.
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Madera S, et al. Among authors: schillaci r. Cell Death Dis. 2022 May 9;13(5):447. doi: 10.1038/s41419-022-04855-0. Cell Death Dis. 2022. PMID: 35534460 Free PMC article.
Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.
Madera S, Chervo MF, Chiauzzi VA, Pereyra MG, Venturutti L, Izzo F, Roldán Deamicis A, Guzman P, Dupont A, Roa JC, Cenciarini ME, Barchuk S, Figurelli S, Lopez Della Vecchia D, Levit C, Lebersztein G, Anfuso F, Castiglioni T, Cortese E, Ares S, Deza EG, Gercovich FG, Proietti CJ, Schillaci R, Cordo Russo RI, Elizalde PV. Madera S, et al. Among authors: schillaci r. Horm Cancer. 2020 Oct;11(5-6):218-239. doi: 10.1007/s12672-020-00392-4. Epub 2020 Jul 6. Horm Cancer. 2020. PMID: 32632815 Free PMC article.
Retraction Note: Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
Flaqué MCD, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo RC, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano MF, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV. Flaqué MCD, et al. Among authors: schillaci r. Breast Cancer Res. 2023 Nov 2;25(1):133. doi: 10.1186/s13058-023-01735-z. Breast Cancer Res. 2023. PMID: 37919764 Free PMC article. No abstract available.
Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy.
De Martino M, Tkach M, Bruni S, Rocha D, Mercogliano MF, Cenciarini ME, Chervo MF, Proietti CJ, Dingli F, Loew D, Fernández EA, Elizalde PV, Piaggio E, Schillaci R. De Martino M, et al. Among authors: schillaci r. Oncoimmunology. 2020 Jan 29;9(1):1715767. doi: 10.1080/2162402X.2020.1715767. eCollection 2020. Oncoimmunology. 2020. PMID: 32064174 Free PMC article.
43 results